Trial site
The Beatson Hospital
Glasgow, G12 OYN, United KingdomNot linked to an institution yet
- 8running trials
- 1closed trial
The trials here
What the 9 trials at this site are about, from their registry records.
- Phase
- Phase 2/38 trials
- Phase 1/21 trial
- Status
- Recruiting7 trials
- Completed1 trial
- Not yet recruiting1 trial
- Lead sponsor
- Cancer Research UK9 trials
Running trials
Recruiting
DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.
NCT07440290· Phase 2/3· Cancer Research UK· Source
Contact: Patricia Roxburgh, Dr
Recruiting
DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers.
NCT05770544· Phase 2/3· Cancer Research UK· Source
Contact: Patricia Roxburgh, Dr
Recruiting
DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations
NCT06988475· Phase 2/3· Cancer Research UK· Source
Contact: Patricia Roxburgh, Dr
Recruiting
DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers
NCT05770037· Phase 2/3· Cancer Research UK· Source
Contact: Patricia Roxburgh, Dr
Recruiting
DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition
NCT05770102· Phase 2/3· Cancer Research UK· Source
Contact: Patricia Roxburgh, Dr
Recruiting
DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations
NCT05786716· Phase 2/3· Cancer Research UK· Source
Contact: Patricia Roxburgh, Dr
Recruiting
DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.
NCT05768178· Phase 2/3· Cancer Research UK· Source
Contact: Patricia Roxburgh, Dr
Recruiting
DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol
NCT05722886· Phase 2/3· Cancer Research UK· Source
Contact: Patricia Roxburgh, Dr
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error